Drug therapies for cognitive impairment and dementia.

J Psychosoc Nurs Ment Health Serv

Psychiatry, University of Pittburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA.

Published: April 2010

Drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease include acetylcholinesterase inhibitor drugs (tacrine [Cognex®], donepezil [Aricept®], rivastigmine [Exelon®, Exelon Patch®], and galantamine [Reminyl®, Razadyne®]) and glutamate-modulating drugs (memantine [Namenda®]). They do not halt the underlying degenerative process but can slow disease progression. Piracetam is a nonprescription noot ropic drug designated by the FDA as an orphan drug for myoclonic seizures. Clinical trials in a diverse group of patients with age-related dementia or cognitive impairment demonstrated a significant benefit, but the methodology of these studies is poor, and long-term effects are unknown. Other therapies discussed in this article include Ginkgo biloba, a nonprescription natural supplement, and Axona", designated by the FDA as a medical food.

Download full-text PDF

Source
http://dx.doi.org/10.3928/02793695-20100311-01DOI Listing

Publication Analysis

Top Keywords

cognitive impairment
8
designated fda
8
drug
4
drug therapies
4
therapies cognitive
4
impairment dementia
4
dementia drugs
4
drugs currently
4
currently approved
4
approved food
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!